CureVac

We are pleased to share that we will be presenting posters at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.   Of note, we will be sharing preliminary safety, tolerability and expanded immunogenicity results from the dose-escalation part of our ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma.   You can find more information in today’s press release here: https://lnkd.in/e_ggKaS3   #SITC24 #Glioblastoma #CancerVaccine #mRNA

We were pleased to collaborate with Moderna, BioNTech SE and PharmaLex in authoring a paper that just published in the American Society of Gene & Cell Therapy journal Molecular Therapy Methods & Clinical Development. The article, titled: What’s in a word – Defining “gene therapy medicines,” explores the growing challenge of appropriately categorizing medicines like mRNA technology for regulatory purposes, and the drawbacks of incorporating it within the same category as other interventions that may involve permanent, direct and extensive modification of the genome. We propose an approach that focuses on the mechanism of a therapy rather than its material components, and its impact on a patient’s genome.    It is important to keep in mind that terminology does not only shape public perception but can have profound regulatory implications that may impact the development and approval of medicines and their potential to contribute to advancing human health.     Click here to read the full article:  https://lnkd.in/eRtb5eM6 #GeneticMedicine #mRNA #MolecularTherapy #ASGCT

🍂 Autumn is here – and that means flu season is upon us 🍂 So, let's not forget to take care of ourselves!   Sharing a friendly reminder to all to get your flu shot and COVID-19 vaccine as we enter into the final stretch of the year.   By staying up to date with your vaccinations, you’re not only protecting yourself but also helping to keep our communities safe. Let’s all do our part to keep each other as healthy as possible!   #FluShot #COVID19 #Vaccination #StayHealthy #CommunityCare

Today we spent time at the Chardan 8th Annual Genetic Medicines Conference, where Our Chief Business Officer Thaminda Ramanayake participated in an insightful fireside chat, discussing CureVac’s vision, near-term focus and the role of #mRNA in elevating the genetic medicines landscape.     It was a great opportunity to hear from both investors and other innovators on a range of important topics driving medical innovation forward, and we were proud to be able to offer our unique perspective.   #mRNA #GeneticMedicine #Oncology #Chardan #Biotech

Our Chief Business Officer Thaminda Ramanayake will be heading to New York City next week to participate in a fireside chat during the Chardan 8th Annual Genetic Medicines Conference.   We greatly look forward to connecting with investors and peer companies as we all come together to discuss the future of genetic medicine and its many possibilities.   #mRNA #HealthcareInnovation #Chardan #Biotech

We're excited to announce that our colleague Roland Böttger, Senior Scientist at CureVac, will be speaking at the 3rd Lipid Nanoparticle Development Summit, taking place in Berlin September 24-26. This event brings together leading experts in the field to discuss the latest advancements in lipid nanoparticle technology—a crucial area in drug delivery and vaccine development.   Roland will be sharing his insights tomorrow in a seminar titled: An mRNA-LNP Vaccine Platform Tailoring the Immunogenicity Profile from Prophylactic to Therapeutic Applications, Reducing Reactogenicity and Extending Shelf-Life Stability.   Looking forward to connecting with everyone at the summit!   #LipidNanoparticles #HealthcareInnovation #DrugDelivery

We are pleased to announce that our CSO, Dr. Myriam Mendila has been invited to speak at the very first Hamburg Science Summit on September 19, 2024. Hosted by the Koerber Stiftung and Hamburg's Ministry of Science, this prestigious event will gather leading figures from science, politics, business, and NGOs to discuss critical topics impacting Europe’s future. This year's summit will center on Europe's technological sovereignty, addressing how Europe can maintain competitiveness in vital areas such as artificial intelligence, energy storage, and medical technologies. Myriam will be part of a distinguished panel titled "The Future of Health: Medical Breakthroughs Made in Europe," alongside Maria Blasco from the Spanish National Cancer Center and Iordanis Arzimanoglou from the European Innovation Council. This one-hour discussion will delve into the future of breakthrough innovation in health and medicine in Europe. Find out more about this event: https://lnkd.in/dE3NhK3d #Science #hamburgsciencesummit #healthcare

Today, CureVac joins the global community in recognizing World Patient Safety Day 🌎 This important day, established by the World Health Organization (WHO) in 2019, aims to raise awareness and drive actions to improve the safety of patients worldwide.   Every year, a new theme is selected for this global awareness day – this year’s theme is “improving diagnosis for patient safety”. An incorrect diagnosis, even minor, can unfortunately be a major roadblock to someone receiving the care they need.   But there are many critical elements at play when it comes to patient safety that go beyond an initial diagnosis journey.   At CureVac, patient safety is at the heart of everything we do. And we are committed to working to develop innovative mRNA therapies with the highest safety standards to ensure the well-being of patients across the globe.   #WorldPatientSafetyDay #PatientSafety #CureVac #Healthcare #Innovation #mRNA   For more information on World Patient Safety Day, visit: https://lnkd.in/gjS5EjV

🏃♂️ Reflecting on the Tübinger Erbe Lauf 2024! 🏃♀️ We were delighted to have sponsored our employees' participation in this fantastic event, supporting our community and celebrating the spirit of sportsmanship and togetherness. It was great to see so many participants come together for a day full of energy, smiles, and incredible achievements - and all of it for a good cause. A special shoutout to our RNA people who took part in the run—they had a blast! Looking forward to next year already! 🏅 #TübingerErbeLauf #CommunitySupport #TeamRNA #ProudSponsor #RunningForFun

Yesterday was an exciting day for us as the first in-human data from our Phase 1 study of our cancer vaccine candidate CVGBM was presented by the brilliant Professor Ghazaleh Tabatabai at the ESMO - European Society for Medical Oncology Congress 2024. Expanding on that excitement, our team was very pleased to see that #ESMODailyReporter selected our data as a highlight of Day 1 of the conference.   You can check out the full article here: https://bit.ly/47taIWZ   #ESMO2024 #mRNA